DUGGAN ROBERT W 4

What Happened Robert W. Duggan, CEO of Summit Therapeutics, reported a purchase of 3,810,000 common shares on June 12, 2026. The shares were acquired at $13.12 each for a total transaction value of $49,987,200. The Form 4 classifies the transaction as a purchase (code P) — a direct buy rather than a sale.

Key Details

• Transaction date: 2026-06-12
• Price per share: $13.12
• Shares acquired: 3,810,000
• Total value: $49,987,200
• Transaction type: P (Purchase — open market or private purchase as reported)
• Shares owned after transaction: Not stated in the provided filing
• Footnote: The filing includes a disclaimer (F1) stating the reporting person "disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein..."
• Filing timeliness: Reported with period date 2026-06-12 and filed 2026-06-12; no late filing indicated in the provided data

Context Purchases by executives are often watched by investors as a potential bullish signal because they represent insiders adding to their holdings, but filings do not state the insider’s motivation. The footnote disclaimer may limit claims of beneficial ownership beyond any stated pecuniary interest; this is a common legal clarification and does not change the recorded purchase.